Rita Jain
Director/Board Member at CELLDEX THERAPEUTICS, INC.
Net worth: 108 544 $ as of 2024-05-30
Profile
Rita I.
Jain is currently serving as an Independent Director at AnaptysBio, Inc., Celldex Therapeutics, Inc., and as a Member-Supervisory Board at AM-Pharma Holding BV and AM-Pharma BV.
Previously, she held positions as the Chief Medical Officer, Executive Director & EVP at ChemoCentryx, Inc., Director at Provention Bio, Inc., Vice President-Pharmaceutical Development at Abbott Laboratories, Vice President-Health & Metabolic Development at AbbVie, Inc., Chief Medical Officer & Senior Vice President at Akebia Therapeutics, Inc., and Chief Medical Officer & Senior Vice President at Immunovant, Inc. She also has experience as an Assistant Professor at New York University School of Medicine.
Dr. Jain received her undergraduate degree from Long Island University and her doctorate from Stony Brook University School of Medicine.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
ANAPTYSBIO, INC.
0.02% | 2024-06-14 | 4,534 ( 0.02% ) | 108 544 $ | 2024-05-30 |
| 2024-06-12 | 0 ( -.--% ) | - $ | 2024-05-30 |
Rita Jain active positions
| Companies | Position | Start |
|---|---|---|
| CELLDEX THERAPEUTICS, INC. | Director/Board Member | 2023-02-15 |
| ANAPTYSBIO, INC. | Director/Board Member | 2023-04-05 |
AM-Pharma Holding BV
 AM-Pharma Holding BV Pharmaceuticals: MajorHealth Technology AM-Pharma Holding BV operates as a financial holding company with interests in the bio-medical sector. The company was founded by Rudd Brands and is headquartered in Bunnik, Netherlands. | Director/Board Member | 2020-06-30 |
AM-Pharma BV
 AM-Pharma BV BiotechnologyHealth Technology AM-Pharma BV operates as a biopharmaceutical company. It engages in the development of proprietary recombinant human Alkaline Phosphatase. The firm’s products include Acute Kidney Injury, Inflammatory Bowel Diseases and Hypophosphatasia. The company was founded in 2001 and is headquartered in Bunnik, the Netherlands. | Director/Board Member | 2019-12-31 |
Former positions of Rita Jain
| Companies | Position | End |
|---|---|---|
| PROVENTION BIO, INC. | Director/Board Member | 2023-04-26 |
| CHEMOCENTRYX, INC. | Chief Tech/Sci/R&D Officer | 2022-10-19 |
| IMMUNOVANT, INC. | Chief Tech/Sci/R&D Officer | 2021-05-31 |
| AKEBIA THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 2019-06-16 |
| ABBVIE INC. | Corporate Officer/Principal | 2011-12-31 |
Training of Rita Jain
| Long Island University | Undergraduate Degree |
| Stony Brook University School of Medicine | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 6 |
|---|---|
| AKEBIA THERAPEUTICS, INC. | Health Technology |
| ABBVIE INC. | Health Technology |
| ABBOTT LABORATORIES | Health Technology |
| IMMUNOVANT, INC. | Health Technology |
| CELLDEX THERAPEUTICS, INC. | Health Services |
| ANAPTYSBIO, INC. | Health Technology |
| Private companies | 5 |
|---|---|
ChemoCentryx, Inc.
 ChemoCentryx, Inc. Pharmaceuticals: MajorHealth Technology ChemoCentryx, Inc. is a biopharmaceutical company, which engages in the development and commercialization of medicines. It focuses on inflammatory disorders, autoimmune diseases, and cancer. Its drug candidates such as Avacopan and CCX140, selectively blocks a specific chemoattractant receptor, leaving the rest of the immune system intact. The company was founded by Thomas J. Schall in 1997 and is headquartered in San Carlos, CA. | Health Technology |
North Shore University Hospital
 North Shore University Hospital Hospital/Nursing ManagementHealth Services North Shore University Hospital Manhasset provided health care services. The company was headquartered in Manhasset, NY. | Health Services |
AM-Pharma Holding BV
AM-Pharma Holding BV Pharmaceuticals: MajorHealth Technology AM-Pharma Holding BV operates as a financial holding company with interests in the bio-medical sector. The company was founded by Rudd Brands and is headquartered in Bunnik, Netherlands. | Health Technology |
AM-Pharma BV
AM-Pharma BV BiotechnologyHealth Technology AM-Pharma BV operates as a biopharmaceutical company. It engages in the development of proprietary recombinant human Alkaline Phosphatase. The firm’s products include Acute Kidney Injury, Inflammatory Bowel Diseases and Hypophosphatasia. The company was founded in 2001 and is headquartered in Bunnik, the Netherlands. | Health Technology |
Provention Bio, Inc.
 Provention Bio, Inc. Pharmaceuticals: MajorHealth Technology Provention Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics and solutions. Its products include PRV-031 for the interception of type 1 diabetes (T1D), PRV-015 for the treatment of gluten-free diet non-responding celiac disease, PRV-6527 for Crohn’s disease, PRV-3279 for the treatment of lupus, and PRV-101 for the prevention of acute coxsackie virus B (CVB), and the prevention of type 1 diabetes (T1D) onset. The company was founded by Francisco Leon and Ashleigh Palmer on October 4, 2016 and is headquartered in Red Bank, NJ. | Health Technology |
- Stock Market
- Insiders
- Rita Jain
